Reading About GLP-1 Agonists on the Internet: How to Recognize Myth vs. Fact
Social media can be a place to learn about people’s experiences with weight-loss medications.
You may see a range of opinions about GLP-1 agonists for weight loss on the internet. Social media can be a great place to learn about people’s experiences taking semaglutide and similar medications. At the same time, you may also find a lot of misinformation or opinions that fuel stigma.
In this video, learn tips for navigating the internet when researching GLP-1 agonists for weight loss, according to Preeti Parikh, MD, Executive Medical Director at GoodRx.
References
Abrams, Z. (2022). The burden of weight stigma. American Psychological Association.
Collins, L., et al. (2023). Glucagon-like peptide-1 receptor agonists. StatPearls.
Latif, W., et al. (2023). Compare and contrast the glucagon-like peptide receptor agonists (GLP1RAs). StatPearls.
Suarez-Lledo, V., et al. (2021). Prevalence of health misinformation on social media: Systematic review. Journal of Medical Internet Research.
U.S. Department of Health and Human Services. (2023). Health misinformation.
Save every month on GLP-1 meds with GoodRx
Save an average of $235 on FDA-approved GLP-1s like Ozempic and Zepbound.
